Oncocyte Files 8-K for Jan 22 Event; Routine Disclosure
Ticker: IMDX · Form: 8-K · Filed: Jan 23, 2024 · CIK: 1642380
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, 8-K, disclosure
TL;DR
**Oncocyte filed a routine 8-K, no major news yet.**
AI Summary
Oncocyte Corporation filed an 8-K on January 23, 2024, reporting an event that occurred on January 22, 2024. This filing is a routine disclosure under Regulation FD and includes financial statements and exhibits. For investors, this filing indicates standard compliance with SEC regulations, but without further details on the specific event, it doesn't immediately signal a major change in the company's operational or financial outlook, making it a neutral event for stock owners.
Why It Matters
This filing is a standard regulatory update, indicating the company is maintaining compliance. Without specific details on the event, it's unlikely to have an immediate impact on stock price.
Risk Assessment
Risk Level: low — The filing itself is a standard regulatory disclosure and does not inherently introduce new risks or opportunities without further context on the event it reports.
Analyst Insight
Investors should monitor for subsequent filings or press releases from Oncocyte Corporation that provide specific details about the event mentioned in this 8-K, as this filing itself is purely administrative.
Key Players & Entities
- Oncocyte Corporation (company) — the registrant filing the 8-K
- January 22, 2024 (date) — date of the earliest event reported
- January 23, 2024 (date) — date the 8-K was filed
- Nasdaq Stock Market LLC (company) — exchange where Oncocyte's common stock is registered
- OCX (company) — trading symbol for Oncocyte Corporation
FAQ
What is the purpose of this 8-K filing by Oncocyte Corporation?
This 8-K filing by Oncocyte Corporation is a 'Current Report' pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 22, 2024.
What is the trading symbol and exchange for Oncocyte Corporation's common stock?
Oncocyte Corporation's common stock has the trading symbol 'OCX' and is registered on 'The Nasdaq Stock Market LLC'.
What is Oncocyte Corporation's business address and phone number?
Oncocyte Corporation's business address is 15 Cushing, Irvine, California 92618, and its telephone number is (949) 409-7600.
What is the Central Index Key (CIK) for Oncocyte Corporation?
The Central Index Key (CIK) for Oncocyte Corporation is 0001642380.
Filing Stats: 632 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-01-23 16:39:38
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- ex99-1_002.jpg (GRAPHIC) — 122KB
- 0001493152-24-003465.txt ( ) — 387KB
- ocx-20240122.xsd (EX-101.SCH) — 3KB
- ocx-20240122_lab.xml (EX-101.LAB) — 33KB
- ocx-20240122_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: January 23, 2024 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer